Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05061693 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
A Phase 2 study of Prurigo Nodularis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 20
- Study locations
NCT05061693: Completed Phase 2 study of Prurigo Nodularis, sponsored by Incyte Corporation.
NCT05061693 is a Phase 2 study of Prurigo Nodularis that has completed, run by Incyte Corporation. The registered enrollment target is 146 participants, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05061693, a Phase 2 study of Prurigo Nodularis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
Primary Outcome
Each evening, the participants assessed their worst level of itch during the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable). The Baseline Itch NRS score was determined by averaging the 7 daily Itch NRS scores before Day 1 (i.e., Day -7 to Day -1). If ≥4 of the 7 days of the daily Itch NRS scores were missing prior to Day 1, then the Baseline Itch NRS score was set to "missing." The by-visit Itch NRS score for postbaseline visits was determined by averaging the 7 daily Itch
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INCB054707
Study Locations (20)
Florida
- Investigative Site US019 - Fort Lauderdale
- Investigative Site US016 - Miami
- Investigative Site US013 - Miramar
- Investigative Site US009 - Tampa
Ohio
- Investigative Site US023 - Athens
- Investigative Site US002 - Dublin
- Investigative Site US012 - Gahanna
Arizona
- Investigative Site US010 - Phoenix
- Investigative Site US024 - Phoenix
California
- Investigative Site US001 - Fountain Valley
- Investigative Site US014 - Sacramento
Indiana
- Investigative Site US008 - Plainfield
- Investigative Site US011 - South Bend
Georgia
- Investigative Site 1071320 - Newnan
Maryland
- Investigative Site US003 - Baltimore
Michigan
- Investigative Site US017 - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2021-11-04 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 2 |
What the finished NCT05061693 record still lists
NCT05061693 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05061693 names 20 study sites across 12 states, led by Florida, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT05061693 about?
NCT05061693 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis". The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.
What is the current status of trial NCT05061693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2021-11-04. Estimated completion is 2024-02-28.
What conditions does trial NCT05061693 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT05061693?
The interventions under investigation include: Placebo (DRUG), INCB054707 (DRUG).
Who is sponsoring clinical trial NCT05061693?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05061693 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05061693's enrollment target sits among peer trials
146 8th of 14 higher than 7 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Barzolvolimab in Patients With Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of CC-10004 for Prurigo Nodularis
COMPLETED · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI